Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Large B-cell Lymphoma (LBCL)”

27 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 27 results

Large-scale testing (Phase 3)Ended earlyNCT05664217
What this trial is testing

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Who this might be right for
Non-Hodgkin LymphomaRelapsed/Refractory Diffuse Large B-cell Lymphoma
Nektar Therapeutics 15
Testing effectiveness (Phase 2)Looking for participantsNCT06526793
What this trial is testing

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

Who this might be right for
B-cell Non-Hodgkin LymphomaFollicular Lymphoma (FL)Large B-Cell Lymphoma (LBCL)
AstraZeneca 240
Testing effectiveness (Phase 2)Looking for participantsNCT04844866
What this trial is testing

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Who this might be right for
Diffuse Large B-cell Lymphoma
Miltenyi Biomedicine GmbH 213
Not applicableLooking for participantsNCT07524816
What this trial is testing

Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma

Who this might be right for
Large B-Cell Lymphoma (LBCL)
N.N. Alexandrov National Cancer Centre 76
Testing effectiveness (Phase 2)Looking for participantsNCT06905509
What this trial is testing

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements+11 more
Joseph Tuscano
Testing effectiveness (Phase 2)Looking for participantsNCT06542250
What this trial is testing

Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Who this might be right for
B-cell Malignancies
AstraZeneca 174
Testing effectiveness (Phase 2)Looking for participantsNCT06489808
What this trial is testing

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

Who this might be right for
Relapsed/Refractory Large B-Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 89
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07447726
What this trial is testing

Exploratory Clinical Study on the Safety and Efficacy of CD19X CAR-T Cell Injection in the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Who this might be right for
Large B-Cell Lymphoma (LBCL)
Institute of Hematology & Blood Diseases Hospital, China 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT07461831
What this trial is testing

CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma

Who this might be right for
Large B-Cell Lymphoma (LBCL)
Beijing Tongren Hospital 100
Testing effectiveness (Phase 2)Looking for participantsNCT06479356
What this trial is testing

CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

Who this might be right for
Non-Hodgkin LymphomaLarge B-cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd. 12
Testing effectiveness (Phase 2)Looking for participantsNCT07098364
What this trial is testing

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+9 more
Fred Hutchinson Cancer Center 33
Not applicableUnknownNCT06142175
What this trial is testing

Relmacabtagene Autoleucel in Patients With LBCL

Who this might be right for
Large B-cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd. 200
Testing effectiveness (Phase 2)Looking for participantsNCT07240194
What this trial is testing

The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study

Who this might be right for
Large B-cell LymphomaTP53
The First Affiliated Hospital with Nanjing Medical University 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07269639
What this trial is testing

Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Large B-Cell Lymphoma (LBCL)
Seoul National University Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT07538635
What this trial is testing

CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.

Who this might be right for
High-risk R/R LBCL
Zhejiang Cancer Hospital 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07613788
What this trial is testing

Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL

Who this might be right for
Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Ruijin Hospital 100
Testing effectiveness (Phase 2)Ended earlyNCT05972720
What this trial is testing

Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

Who this might be right for
CancerRelapsed/Refractory Large B-cell Lymphoma (LBCL)
CARGO Therapeutics 101
Testing effectiveness (Phase 2)Active Not RecruitingNCT04416984
What this trial is testing

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Who this might be right for
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Allogene Therapeutics 160
Early research (Phase 1)Ended earlyNCT06256484
What this trial is testing

Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Atara Biotherapeutics 1
Not applicableUnknownNCT05800067
What this trial is testing

Axi-cel Retreatment in Relapsed/Refractory LBCL

Who this might be right for
CAR-T Retreatment
Ruijin Hospital 32
Load More Results
25